Could a 'smart' stem cell transplant free patients from a lifetime of anti-rejection drugs?
NCT ID NCT04678401
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase study tests a new stem cell transplant method for people with aggressive or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially engineered donor cells to reduce the risk of graft-versus-host disease, potentially allowing patients to avoid lifelong immunosuppressive drugs. Up to 30 participants will receive radiation, chemotherapy, and an infusion of regulatory T-cell enriched donor stem cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Regulatory T-cell enriched donor stem cells
What this could lead to
If successful, this approach could allow patients with aggressive leukemia or MDS to receive a stem cell transplant without needing lifelong anti-rejection drugs.
What could go wrong
This is a very early phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of graft failure, severe infection, or graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.